Lisa Schilling
Concepts (383)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 14 | 2026 | 1176 | 1.350 |
Why?
| | Periodicals as Topic | 11 | 2008 | 206 | 1.220 |
Why?
| | Decision Support Systems, Clinical | 2 | 2022 | 269 | 1.060 |
Why?
| | Comparative Effectiveness Research | 4 | 2017 | 167 | 0.900 |
Why?
| | Patient-Centered Care | 2 | 2024 | 545 | 0.900 |
Why?
| | Quality Improvement | 7 | 2025 | 1287 | 0.880 |
Why?
| | Data Mining | 2 | 2017 | 115 | 0.830 |
Why?
| | Medical Informatics | 5 | 2024 | 96 | 0.820 |
Why?
| | Information Storage and Retrieval | 7 | 2021 | 122 | 0.780 |
Why?
| | Needs Assessment | 2 | 2025 | 401 | 0.770 |
Why?
| | Decision Support Techniques | 2 | 2025 | 461 | 0.760 |
Why?
| | Publishing | 7 | 2007 | 115 | 0.750 |
Why?
| | Maternal Health Services | 1 | 2024 | 102 | 0.740 |
Why?
| | Ultraviolet Rays | 6 | 2015 | 384 | 0.720 |
Why?
| | Hypertension | 6 | 2025 | 1262 | 0.700 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 206 | 0.670 |
Why?
| | Critical Pathways | 1 | 2022 | 108 | 0.670 |
Why?
| | Dermatology | 8 | 2021 | 128 | 0.630 |
Why?
| | Primary Health Care | 9 | 2026 | 1730 | 0.580 |
Why?
| | Skin Neoplasms | 7 | 2015 | 850 | 0.570 |
Why?
| | Sunbathing | 2 | 2015 | 16 | 0.570 |
Why?
| | Internet | 10 | 2018 | 698 | 0.550 |
Why?
| | Blood Pressure Determination | 1 | 2018 | 143 | 0.520 |
Why?
| | Internal Medicine | 6 | 2025 | 278 | 0.500 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 438 | 0.480 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 732 | 0.480 |
Why?
| | Medical Record Linkage | 4 | 2024 | 68 | 0.460 |
Why?
| | Safety-net Providers | 2 | 2019 | 128 | 0.450 |
Why?
| | Biomedical Research | 5 | 2021 | 712 | 0.440 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 132 | 0.430 |
Why?
| | Remote Consultation | 2 | 2026 | 66 | 0.430 |
Why?
| | Humans | 80 | 2026 | 144665 | 0.420 |
Why?
| | Leadership | 2 | 2024 | 400 | 0.410 |
Why?
| | Foot Deformities, Congenital | 1 | 2013 | 1 | 0.410 |
Why?
| | Melanoma | 4 | 2021 | 757 | 0.410 |
Why?
| | Health Maintenance Organizations | 2 | 2011 | 105 | 0.410 |
Why?
| | Myotonic Dystrophy | 1 | 2013 | 10 | 0.400 |
Why?
| | Contracture | 1 | 2013 | 23 | 0.400 |
Why?
| | Attitude of Health Personnel | 4 | 2016 | 1180 | 0.400 |
Why?
| | Spinal Diseases | 1 | 2013 | 50 | 0.390 |
Why?
| | Benchmarking | 2 | 2011 | 189 | 0.390 |
Why?
| | Quality Indicators, Health Care | 3 | 2010 | 335 | 0.390 |
Why?
| | Surveys and Questionnaires | 12 | 2022 | 6041 | 0.380 |
Why?
| | Algorithms | 5 | 2025 | 1843 | 0.370 |
Why?
| | Peer Review, Research | 3 | 2007 | 36 | 0.370 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 299 | 0.360 |
Why?
| | Drug Monitoring | 1 | 2016 | 396 | 0.360 |
Why?
| | Databases, Factual | 6 | 2024 | 1494 | 0.360 |
Why?
| | Beauty Culture | 4 | 2005 | 11 | 0.360 |
Why?
| | Bone Diseases, Metabolic | 2 | 2022 | 58 | 0.350 |
Why?
| | United States | 28 | 2026 | 16018 | 0.350 |
Why?
| | Total Quality Management | 1 | 2010 | 57 | 0.320 |
Why?
| | Databases, Bibliographic | 3 | 2004 | 30 | 0.320 |
Why?
| | Information Management | 2 | 2012 | 16 | 0.310 |
Why?
| | Transgender Persons | 2 | 2023 | 207 | 0.290 |
Why?
| | Fractures, Bone | 1 | 2013 | 417 | 0.280 |
Why?
| | Information Dissemination | 1 | 2010 | 222 | 0.270 |
Why?
| | Models, Statistical | 1 | 2012 | 677 | 0.270 |
Why?
| | Tretinoin | 1 | 2009 | 124 | 0.270 |
Why?
| | Middle Aged | 26 | 2026 | 35968 | 0.260 |
Why?
| | Health Services Accessibility | 2 | 2026 | 1098 | 0.260 |
Why?
| | Female | 36 | 2026 | 78301 | 0.260 |
Why?
| | Adult | 23 | 2026 | 40486 | 0.250 |
Why?
| | Ambulatory Care | 4 | 2025 | 607 | 0.250 |
Why?
| | Aged | 21 | 2026 | 25955 | 0.240 |
Why?
| | Anticholesteremic Agents | 2 | 2005 | 154 | 0.240 |
Why?
| | Cause of Death | 1 | 2009 | 464 | 0.240 |
Why?
| | Disclosure | 1 | 2007 | 84 | 0.240 |
Why?
| | Internship and Residency | 4 | 2006 | 1262 | 0.240 |
Why?
| | Access to Information | 1 | 2006 | 47 | 0.240 |
Why?
| | Ambulatory Care Facilities | 2 | 2026 | 267 | 0.240 |
Why?
| | Clofibric Acid | 1 | 2005 | 1 | 0.230 |
Why?
| | Physician-Patient Relations | 5 | 2002 | 589 | 0.230 |
Why?
| | Adolescent | 20 | 2024 | 22405 | 0.220 |
Why?
| | Male | 36 | 2026 | 72425 | 0.220 |
Why?
| | Office Visits | 2 | 2002 | 92 | 0.220 |
Why?
| | Libraries, Digital | 1 | 2004 | 4 | 0.220 |
Why?
| | Archives | 1 | 2004 | 5 | 0.220 |
Why?
| | Rheumatic Diseases | 1 | 2026 | 97 | 0.210 |
Why?
| | Observational Studies as Topic | 1 | 2025 | 131 | 0.210 |
Why?
| | Health Information Interoperability | 1 | 2024 | 3 | 0.210 |
Why?
| | Spain | 5 | 2021 | 49 | 0.210 |
Why?
| | Gemfibrozil | 2 | 2006 | 9 | 0.210 |
Why?
| | Comorbidity | 7 | 2022 | 1652 | 0.210 |
Why?
| | Rheumatology | 1 | 2026 | 133 | 0.210 |
Why?
| | Biological Products | 2 | 2024 | 256 | 0.210 |
Why?
| | Lovastatin | 2 | 2006 | 37 | 0.210 |
Why?
| | Platelet Transfusion | 1 | 2024 | 78 | 0.200 |
Why?
| | Legislation as Topic | 1 | 2003 | 5 | 0.200 |
Why?
| | Antihypertensive Agents | 2 | 2025 | 512 | 0.190 |
Why?
| | Pharmacists | 1 | 2025 | 240 | 0.190 |
Why?
| | Osteoporotic Fractures | 1 | 2023 | 61 | 0.190 |
Why?
| | Anticarcinogenic Agents | 1 | 2003 | 61 | 0.190 |
Why?
| | Meningocele | 1 | 2022 | 2 | 0.190 |
Why?
| | Emergency Service, Hospital | 2 | 2026 | 2325 | 0.190 |
Why?
| | Programming Languages | 2 | 2021 | 25 | 0.180 |
Why?
| | Osteochondroma | 1 | 2022 | 10 | 0.180 |
Why?
| | Cohort Studies | 9 | 2025 | 5957 | 0.180 |
Why?
| | Hospitalization | 6 | 2022 | 2446 | 0.180 |
Why?
| | Young Adult | 10 | 2023 | 14119 | 0.180 |
Why?
| | Aged, 80 and over | 9 | 2026 | 8283 | 0.180 |
Why?
| | Erythrocyte Transfusion | 1 | 2024 | 226 | 0.180 |
Why?
| | Blood-Retinal Barrier | 1 | 2021 | 13 | 0.170 |
Why?
| | Computer Communication Networks | 1 | 2021 | 32 | 0.170 |
Why?
| | Patient Acceptance of Health Care | 3 | 2023 | 881 | 0.170 |
Why?
| | Drug Repositioning | 1 | 2021 | 40 | 0.170 |
Why?
| | Osteoporosis | 1 | 2023 | 236 | 0.160 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 479 | 0.160 |
Why?
| | Confidentiality | 1 | 2021 | 80 | 0.160 |
Why?
| | Perception | 1 | 2023 | 376 | 0.160 |
Why?
| | Quality of Health Care | 3 | 2024 | 692 | 0.160 |
Why?
| | Influenza, Human | 3 | 2021 | 618 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 355 | 0.160 |
Why?
| | Natural Language Processing | 1 | 2021 | 103 | 0.160 |
Why?
| | Microvessels | 1 | 2021 | 98 | 0.150 |
Why?
| | Blood-Brain Barrier | 1 | 2021 | 155 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2021 | 427 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2003 | 301 | 0.150 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2201 | 0.150 |
Why?
| | Computational Biology | 1 | 2004 | 681 | 0.150 |
Why?
| | Database Management Systems | 2 | 2012 | 50 | 0.150 |
Why?
| | Pandemics | 4 | 2021 | 1700 | 0.140 |
Why?
| | Patient Satisfaction | 5 | 2025 | 707 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 254 | 0.140 |
Why?
| | Blood Pressure | 1 | 2025 | 1766 | 0.140 |
Why?
| | Alzheimer Disease | 1 | 2025 | 622 | 0.140 |
Why?
| | Asthma | 2 | 2022 | 1774 | 0.140 |
Why?
| | Student Health Services | 1 | 2018 | 15 | 0.140 |
Why?
| | Retina | 1 | 2021 | 319 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 253 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2024 | 586 | 0.140 |
Why?
| | Patient Care Team | 1 | 2024 | 690 | 0.140 |
Why?
| | Occupational Health | 1 | 2021 | 210 | 0.140 |
Why?
| | Language | 1 | 2021 | 323 | 0.130 |
Why?
| | Patient Portals | 1 | 2018 | 49 | 0.130 |
Why?
| | Health Plan Implementation | 1 | 2019 | 141 | 0.130 |
Why?
| | Qualitative Research | 1 | 2025 | 1668 | 0.130 |
Why?
| | Republic of Korea | 3 | 2021 | 42 | 0.130 |
Why?
| | Communication | 2 | 2020 | 972 | 0.120 |
Why?
| | Referral and Consultation | 4 | 2026 | 852 | 0.120 |
Why?
| | Phenotype | 1 | 2025 | 3147 | 0.120 |
Why?
| | Health Care Surveys | 3 | 2016 | 537 | 0.120 |
Why?
| | Authorship | 2 | 2007 | 49 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2009 | 1742 | 0.120 |
Why?
| | Artificial Intelligence | 1 | 2021 | 381 | 0.120 |
Why?
| | Curriculum | 3 | 2024 | 1063 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Review Literature as Topic | 2 | 2006 | 52 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 381 | 0.110 |
Why?
| | Education, Medical | 2 | 2011 | 273 | 0.110 |
Why?
| | Academic Medical Centers | 4 | 2023 | 545 | 0.110 |
Why?
| | Hyperlipidemias | 1 | 2016 | 120 | 0.110 |
Why?
| | Longevity | 1 | 2016 | 175 | 0.110 |
Why?
| | Health Education | 1 | 2018 | 345 | 0.110 |
Why?
| | Advance Care Planning | 1 | 2018 | 243 | 0.110 |
Why?
| | Transcriptome | 1 | 2021 | 1036 | 0.110 |
Why?
| | Retrospective Studies | 5 | 2025 | 17147 | 0.110 |
Why?
| | Drosophila melanogaster | 1 | 2016 | 237 | 0.110 |
Why?
| | Trichotillomania | 1 | 2014 | 5 | 0.110 |
Why?
| | Health Personnel | 1 | 2021 | 746 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1360 | 0.100 |
Why?
| | Prevalence | 4 | 2021 | 2839 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2017 | 578 | 0.100 |
Why?
| | Affective Symptoms | 1 | 2014 | 53 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2025 | 1948 | 0.100 |
Why?
| | Palliative Care | 1 | 2022 | 1011 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1076 | 0.100 |
Why?
| | Colorado | 7 | 2026 | 4558 | 0.090 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 472 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1928 | 0.090 |
Why?
| | France | 2 | 2021 | 40 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1476 | 0.090 |
Why?
| | Medical Records Systems, Computerized | 1 | 2012 | 94 | 0.080 |
Why?
| | Medication Adherence | 1 | 2016 | 540 | 0.080 |
Why?
| | Obesity | 2 | 2022 | 3070 | 0.080 |
Why?
| | Thalassemia | 1 | 2011 | 6 | 0.080 |
Why?
| | Pregnancy | 1 | 2024 | 7122 | 0.080 |
Why?
| | Quality Assurance, Health Care | 2 | 2010 | 341 | 0.080 |
Why?
| | Health Services Research | 2 | 2012 | 392 | 0.080 |
Why?
| | Planning Techniques | 1 | 2010 | 15 | 0.080 |
Why?
| | Organizational Objectives | 1 | 2010 | 66 | 0.080 |
Why?
| | Cost Savings | 1 | 2010 | 85 | 0.080 |
Why?
| | Disaster Planning | 1 | 2011 | 101 | 0.080 |
Why?
| | Heart Diseases | 1 | 2013 | 341 | 0.080 |
Why?
| | Organizational Innovation | 1 | 2010 | 118 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 849 | 0.080 |
Why?
| | Child | 7 | 2021 | 22599 | 0.080 |
Why?
| | Health Records, Personal | 1 | 2010 | 26 | 0.080 |
Why?
| | Child, Preschool | 4 | 2021 | 11789 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 140 | 0.080 |
Why?
| | Safety Management | 1 | 2010 | 124 | 0.070 |
Why?
| | Organizational Culture | 1 | 2010 | 160 | 0.070 |
Why?
| | Brain | 1 | 2021 | 2933 | 0.070 |
Why?
| | Administration, Topical | 1 | 2009 | 152 | 0.070 |
Why?
| | Emotions | 1 | 2014 | 578 | 0.070 |
Why?
| | Program Evaluation | 2 | 2026 | 941 | 0.070 |
Why?
| | Codes of Ethics | 1 | 2008 | 16 | 0.070 |
Why?
| | Human Experimentation | 1 | 2008 | 11 | 0.070 |
Why?
| | Infant | 3 | 2021 | 10022 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2010 | 293 | 0.060 |
Why?
| | Age Factors | 3 | 2020 | 3329 | 0.060 |
Why?
| | Scientific Misconduct | 1 | 2007 | 7 | 0.060 |
Why?
| | Self-Evaluation Programs | 1 | 2007 | 5 | 0.060 |
Why?
| | Lung Diseases | 1 | 2013 | 781 | 0.060 |
Why?
| | Ethics, Research | 1 | 2007 | 33 | 0.060 |
Why?
| | Bibliometrics | 1 | 2007 | 65 | 0.060 |
Why?
| | Public Health | 1 | 2011 | 569 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2006 | 23 | 0.060 |
Why?
| | Family Practice | 1 | 2010 | 402 | 0.060 |
Why?
| | Students, Medical | 2 | 2011 | 374 | 0.060 |
Why?
| | Hypolipidemic Agents | 1 | 2006 | 89 | 0.060 |
Why?
| | Knowledge | 1 | 2006 | 57 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2873 | 0.060 |
Why?
| | Medical Staff, Hospital | 1 | 2006 | 80 | 0.060 |
Why?
| | Vaccination | 2 | 2021 | 1419 | 0.060 |
Why?
| | Research Design | 2 | 2014 | 1129 | 0.060 |
Why?
| | Clinical Clerkship | 1 | 2007 | 109 | 0.060 |
Why?
| | Appointments and Schedules | 1 | 2025 | 96 | 0.050 |
Why?
| | Indiana | 1 | 2024 | 37 | 0.050 |
Why?
| | Health Level Seven | 1 | 2024 | 2 | 0.050 |
Why?
| | Vocabulary, Controlled | 1 | 2024 | 47 | 0.050 |
Why?
| | Data Accuracy | 1 | 2024 | 65 | 0.050 |
Why?
| | Editorial Policies | 1 | 2004 | 46 | 0.050 |
Why?
| | Blood Banks | 1 | 2024 | 50 | 0.050 |
Why?
| | Taxes | 1 | 2003 | 16 | 0.050 |
Why?
| | Teaching | 1 | 2006 | 237 | 0.050 |
Why?
| | Job Satisfaction | 1 | 2025 | 235 | 0.050 |
Why?
| | Managed Care Programs | 2 | 2002 | 140 | 0.050 |
Why?
| | Medical Staff | 1 | 2002 | 17 | 0.050 |
Why?
| | Testosterone Congeners | 1 | 2022 | 7 | 0.050 |
Why?
| | Animals | 5 | 2022 | 37948 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 1406 | 0.050 |
Why?
| | Chemoprevention | 1 | 2003 | 91 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 276 | 0.050 |
Why?
| | Risk Factors | 3 | 2021 | 10796 | 0.050 |
Why?
| | Osteocytes | 1 | 2022 | 24 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2003 | 170 | 0.050 |
Why?
| | Documentation | 1 | 2004 | 198 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 126 | 0.040 |
Why?
| | Smoking Prevention | 1 | 2003 | 166 | 0.040 |
Why?
| | Fibric Acids | 1 | 2021 | 2 | 0.040 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5869 | 0.040 |
Why?
| | X-Ray Microtomography | 1 | 2022 | 107 | 0.040 |
Why?
| | NFATC Transcription Factors | 1 | 2022 | 94 | 0.040 |
Why?
| | Canada | 1 | 2003 | 432 | 0.040 |
Why?
| | Receptors, Notch | 1 | 2022 | 90 | 0.040 |
Why?
| | Common Data Elements | 1 | 2021 | 17 | 0.040 |
Why?
| | Chondrogenesis | 1 | 2022 | 88 | 0.040 |
Why?
| | Blood Platelets | 1 | 2024 | 379 | 0.040 |
Why?
| | Ceftriaxone | 1 | 2021 | 21 | 0.040 |
Why?
| | Lopinavir | 1 | 2021 | 30 | 0.040 |
Why?
| | Administrative Claims, Healthcare | 1 | 2021 | 28 | 0.040 |
Why?
| | Osteoblasts | 1 | 2022 | 146 | 0.040 |
Why?
| | Medical Oncology | 1 | 2004 | 331 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2007 | 915 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2021 | 45 | 0.040 |
Why?
| | Sepsis | 1 | 2007 | 643 | 0.040 |
Why?
| | Germany | 1 | 2021 | 138 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2022 | 212 | 0.040 |
Why?
| | Ritonavir | 1 | 2021 | 75 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 63 | 0.040 |
Why?
| | Abnormalities, Multiple | 1 | 2022 | 197 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 205 | 0.040 |
Why?
| | Enoxaparin | 1 | 2021 | 68 | 0.040 |
Why?
| | China | 1 | 2021 | 269 | 0.040 |
Why?
| | Azithromycin | 1 | 2021 | 105 | 0.040 |
Why?
| | Age Distribution | 1 | 2021 | 402 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 337 | 0.040 |
Why?
| | Osteogenesis | 1 | 2022 | 207 | 0.040 |
Why?
| | Biological Transport | 1 | 2021 | 418 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 136 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2021 | 449 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 393 | 0.040 |
Why?
| | Medically Underserved Area | 1 | 2000 | 100 | 0.040 |
Why?
| | Complementary Therapies | 1 | 2000 | 95 | 0.040 |
Why?
| | Patient Participation | 1 | 2023 | 428 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6399 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 973 | 0.040 |
Why?
| | Safety | 1 | 2021 | 356 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 259 | 0.040 |
Why?
| | Estradiol | 1 | 2022 | 507 | 0.040 |
Why?
| | Software Design | 1 | 2018 | 25 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2023 | 493 | 0.040 |
Why?
| | Burnout, Professional | 1 | 2025 | 483 | 0.040 |
Why?
| | Narration | 1 | 2020 | 78 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 412 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2019 | 119 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2021 | 11734 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2922 | 0.030 |
Why?
| | Skin | 1 | 2003 | 762 | 0.030 |
Why?
| | Occult Blood | 1 | 2018 | 39 | 0.030 |
Why?
| | Erythrocytes | 1 | 2024 | 750 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 480 | 0.030 |
Why?
| | Vitamin D | 1 | 2021 | 400 | 0.030 |
Why?
| | Family | 1 | 2002 | 685 | 0.030 |
Why?
| | Overweight | 1 | 2022 | 606 | 0.030 |
Why?
| | Physicians | 1 | 2006 | 949 | 0.030 |
Why?
| | Fiber Optic Technology | 1 | 1997 | 23 | 0.030 |
Why?
| | Spiro Compounds | 1 | 1996 | 17 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1501 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 547 | 0.030 |
Why?
| | Growth Hormone | 1 | 1996 | 91 | 0.030 |
Why?
| | Intracranial Pressure | 1 | 1997 | 65 | 0.030 |
Why?
| | Sexual Behavior, Animal | 1 | 2016 | 57 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2114 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2022 | 864 | 0.030 |
Why?
| | Testis | 1 | 2016 | 162 | 0.030 |
Why?
| | Smoking | 1 | 2003 | 1467 | 0.030 |
Why?
| | Cooperative Behavior | 2 | 2011 | 464 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 154 | 0.030 |
Why?
| | Colonoscopy | 1 | 2018 | 260 | 0.030 |
Why?
| | United States Public Health Service | 1 | 2015 | 9 | 0.030 |
Why?
| | Prospective Studies | 3 | 2003 | 7994 | 0.030 |
Why?
| | Reproduction | 1 | 2016 | 207 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 288 | 0.030 |
Why?
| | Mice | 2 | 2022 | 18261 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2104 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1996 | 317 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 2 | 2005 | 100 | 0.030 |
Why?
| | Down-Regulation | 1 | 2016 | 616 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2016 | 248 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1766 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 2037 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 944 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1984 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 848 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2018 | 771 | 0.020 |
Why?
| | Time Factors | 2 | 2021 | 7140 | 0.020 |
Why?
| | Data Collection | 2 | 2006 | 635 | 0.020 |
Why?
| | Clinical Competence | 3 | 2007 | 1237 | 0.020 |
Why?
| | Quality of Life | 2 | 2019 | 3183 | 0.020 |
Why?
| | Indoles | 1 | 1996 | 504 | 0.020 |
Why?
| | Rats | 1 | 2021 | 5570 | 0.020 |
Why?
| | Registries | 1 | 2021 | 2392 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1847 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5967 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4081 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2847 | 0.020 |
Why?
| | Problem-Based Learning | 1 | 2011 | 97 | 0.020 |
Why?
| | Schools, Medical | 1 | 2011 | 158 | 0.020 |
Why?
| | Health Surveys | 1 | 2011 | 517 | 0.020 |
Why?
| | MEDLINE | 1 | 2007 | 20 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5185 | 0.020 |
Why?
| | Clofibrate | 1 | 2006 | 3 | 0.020 |
Why?
| | Bezafibrate | 1 | 2006 | 10 | 0.020 |
Why?
| | Pravastatin | 1 | 2006 | 44 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2006 | 67 | 0.020 |
Why?
| | Simvastatin | 1 | 2006 | 59 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1388 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1561 | 0.010 |
Why?
| | Bioterrorism | 1 | 2006 | 31 | 0.010 |
Why?
| | Quality Control | 1 | 2006 | 164 | 0.010 |
Why?
| | Electronic Mail | 1 | 2006 | 59 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2008 | 267 | 0.010 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2006 | 80 | 0.010 |
Why?
| | Research Personnel | 1 | 2007 | 185 | 0.010 |
Why?
| | Pyrroles | 1 | 2006 | 213 | 0.010 |
Why?
| | Hypermedia | 1 | 2004 | 1 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 2006 | 3414 | 0.010 |
Why?
| | Computers | 1 | 2004 | 67 | 0.010 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 205 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1076 | 0.010 |
Why?
| | Beds | 1 | 2003 | 11 | 0.010 |
Why?
| | Educational Measurement | 1 | 2007 | 325 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2006 | 275 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2942 | 0.010 |
Why?
| | Professional Autonomy | 1 | 2002 | 29 | 0.010 |
Why?
| | Gatekeeping | 1 | 2002 | 3 | 0.010 |
Why?
| | Probability | 1 | 2002 | 309 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2573 | 0.010 |
Why?
| | Pilot Projects | 1 | 2007 | 1886 | 0.010 |
Why?
| | Research | 1 | 2004 | 431 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 366 | 0.010 |
Why?
| | Incidence | 1 | 2006 | 2892 | 0.010 |
Why?
| | Outpatients | 1 | 2002 | 447 | 0.010 |
Why?
| | Software | 1 | 2004 | 695 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 164 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2000 | 1322 | 0.010 |
Why?
| | Administration, Oral | 1 | 1996 | 851 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2019 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1996 | 2033 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1997 | 3603 | 0.000 |
Why?
| | Blood Glucose | 1 | 1996 | 2326 | 0.000 |
Why?
|
|
Schilling's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|